In six patient-derived IDH1-mut primary glioma cultures, IDH1-mut glioma cells have proven to be very sensitive to two different BET inhibitors in vitro (the well-established JQ1 compound and GS-626510), with an IC50 value less than 250 nM and achieving maximum cell death of 31 to 77% [71]. This evidence concerns the gene IDH1 and central nervous system cancer.